IMNN READ THE FULL IMNN RESEARCH REPORT Business Update Preparations Underway for Phase 3 Ovarian Cancer Trial; Set to Initiate in 1Q25 Imunon, Inc. (NASDAQ:IMNN) previously reported positive topline ...

Data presented as part of a poster at the SITC 2024 Conference SOUTH SAN FRANCISCO, Calif., Nov. 11, 2024 (GLOBE NEWSWIRE) -- ...

IMNN-001 immunotherapy plus standard-of-care chemotherapy resulted in 35% improvement in overall survival and 25% improvement in progression-free ...

The novel drug SHR-A1921 was safe and efficacious in patients with platinum-resistant ovarian cancer, according to phase 1 data.

The company first kicked off its OASIS trials in October last year at the City of Hope’s NCI-designated comprehensive cancer ...

Compugen (CGEN) has released an update. Compugen Ltd. has announced promising data on the anti-tumor activity and safety of its triple ...

The Ovarian Cancer Research Alliance offers specialized services and support to help ovarian cancer patients find a community and connect with others facing similar challenges. Their Woman to Woman ...

The University of Iowa has been selected among 22 other research teams to participate in the Advanced Research Projects ...

To reduce colorectal cancer risk, being active in both the early morning and evening might provide greater benefits than ...

Former champion billiards player Jeanette Lee, 53, is living with stage 4 ovarian cancer and manages by taking Lynparza.

Liposomal Doxorubicin Market Liposomal Doxorubicin Market Dublin, Nov. 07, 2024 (GLOBE NEWSWIRE) -- The "Liposomal ...

The addition of nivolumab to rucaparib maintenance therapy did not improve progression-free survival (PFS) in patients with ovarian cancer, outcomes of the phase 3 ATHENA-COMBO trial demonstrated. In ...